TY - JOUR
T1 - Non-specific aortoarteritis
T2 - long term follow-up on immunosuppressive therapy
AU - Talwar, Kewal K.
AU - Vasan, Ramachandran S.
AU - Sharma, Sanjiv
AU - Chopra, Prem
AU - Shrivastava, Savitri
AU - Malhotra, Arun
PY - 1993/4
Y1 - 1993/4
N2 - Thirteen patients with non-specific aortoarteritis and endomyocardial biopsy evidence of myocarditis were followed-up on immunosuppressive therapy comprising of prednisolone and cyclophosphamide in addition to conventional treatment for hypertension and/or congestive heart failure. Serial determinations of erythrocyte sedimentation rate, chest roentgenogram, radionuclide ventriculogram and hemodynamic study including endomyocardial biopsy were carried out at 12, 24 and 52 weeks of therapy. Arterial lesions were also assessed by digital subtraction angiography at 0 and 52 weeks of immunosuppressive therapy. At the end of a year of treatment all patients with congestive heart failure ( 10 13) showed symptomatic improvement by at least one New York Heart Association (NYHA) class. There was a significant fall in erythrocyte sedimentation rate (48 ± 12 mm/1st h to 31 ± 12 mm/1st h, P < 0.05), pulmonary artery pressure (32 ± 14 mmHg to 20 ± 9 mmHg, P < 0.05), left ventricular filling pressure (20 ± 11 mmHg to 11 ± 7 mmHg, P < 0.05) and increase in left ventricle ejection fraction (39 ± 16% to 51 ± 14%, P < 0.05) associated with resolution of morphological changes on endomyocardial biopsy. Arterial lesions remained static with neither progression nor appearance of new lesions. No significant complications of therapy were noticed in any patient. Our uncontrolled observations suggest that immunosuppressive therapy is safe and results in clinical, hemodynamic and myocardial morphological improvement in a subset of patients with non-specific aortoarteritis and associated myocarditis.
AB - Thirteen patients with non-specific aortoarteritis and endomyocardial biopsy evidence of myocarditis were followed-up on immunosuppressive therapy comprising of prednisolone and cyclophosphamide in addition to conventional treatment for hypertension and/or congestive heart failure. Serial determinations of erythrocyte sedimentation rate, chest roentgenogram, radionuclide ventriculogram and hemodynamic study including endomyocardial biopsy were carried out at 12, 24 and 52 weeks of therapy. Arterial lesions were also assessed by digital subtraction angiography at 0 and 52 weeks of immunosuppressive therapy. At the end of a year of treatment all patients with congestive heart failure ( 10 13) showed symptomatic improvement by at least one New York Heart Association (NYHA) class. There was a significant fall in erythrocyte sedimentation rate (48 ± 12 mm/1st h to 31 ± 12 mm/1st h, P < 0.05), pulmonary artery pressure (32 ± 14 mmHg to 20 ± 9 mmHg, P < 0.05), left ventricular filling pressure (20 ± 11 mmHg to 11 ± 7 mmHg, P < 0.05) and increase in left ventricle ejection fraction (39 ± 16% to 51 ± 14%, P < 0.05) associated with resolution of morphological changes on endomyocardial biopsy. Arterial lesions remained static with neither progression nor appearance of new lesions. No significant complications of therapy were noticed in any patient. Our uncontrolled observations suggest that immunosuppressive therapy is safe and results in clinical, hemodynamic and myocardial morphological improvement in a subset of patients with non-specific aortoarteritis and associated myocarditis.
KW - Immunosuppressive therapy
KW - Myocarditis
KW - Non-specific aortoarteritis
UR - http://www.scopus.com/inward/record.url?scp=0027285764&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027285764&partnerID=8YFLogxK
U2 - 10.1016/0167-5273(93)90299-V
DO - 10.1016/0167-5273(93)90299-V
M3 - Article
C2 - 8407011
AN - SCOPUS:0027285764
SN - 0167-5273
VL - 39
SP - 79
EP - 84
JO - International Journal of Cardiology
JF - International Journal of Cardiology
IS - 1
ER -